Skip to main
AUPH

Aurinia Pharmaceuticals (AUPH) Stock Forecast & Price Target

Aurinia Pharmaceuticals (AUPH) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Aurinia Pharmaceuticals is projected to generate significant risk-adjusted product revenues, starting at $243.7 million in 2025 and increasing to $932.3 million by 2033. Additionally, the company’s potential aritinercept product could contribute risk-adjusted revenues of $15.4 million in 2030, with expectations of growth to $281.6 million by 2033, contingent upon successful launch and market penetration. Furthermore, the anticipated positive impact from the 2024 ACR LN guidelines is expected to accelerate the growth of LUPKYNIS, heralding a new phase of expansion for the company.

Bears say

Aurinia Pharmaceuticals Inc has faced challenges in gaining traction with its lead product, LUPKYNIS, which may lead to slower revenue growth than anticipated in a competitive biopharmaceutical sector. The company's development pipeline, while promising, is still in the early stages, which presents potential risks related to regulatory approval and market entry, impacting investor confidence. Additionally, recurring expenses related to research and development efforts, coupled with limited financial reserves, raises concerns about the company's ability to sustain operations and fund growth initiatives.

Aurinia Pharmaceuticals (AUPH) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aurinia Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aurinia Pharmaceuticals (AUPH) Forecast

Analysts have given Aurinia Pharmaceuticals (AUPH) a Buy based on their latest research and market trends.

According to 4 analysts, Aurinia Pharmaceuticals (AUPH) has a Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aurinia Pharmaceuticals (AUPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.